The nephrotic syndrome

New England Journal of Medicine

Volumn 338, Issue 17, 1998, Pages 1202-1211

  Orth, Stephan R ^a   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ALPHA INTERFERON; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

EDEMA; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPOVOLEMIA; INFECTION; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN RESTRICTION; PROTEINURIA; REVIEW; SODIUM RETENTION; THROMBOEMBOLISM;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; DIET THERAPY; HUMANS; IMMUNOTHERAPY; NEPHROTIC SYNDROME;

EID: 0032560040     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199804233381707     Document Type: Review

References (108)

1. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996;27:167-94.
2. Lewis EJ. Management of the nephrotic syndrome in adults. In: Cameron JS, Glassock RJ, eds. The nephrotic syndrome. New York: Marcel Dekker, 1988:461-521.
3. Cortes L, Tejani A. Dilemma of focal segmental glomerular sclerosis. Kidney Int Suppl 1996;53:S57-S63.
4. Humphreys MH. Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int 1995;48:311-20.
5. D'Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol 1997;8:138-52.
6. Katz AI, Lindheimer MD. Kidney disease and hypertension in pregnancy. In: Massry SG, Glassock RJ, eds. Textbook of nephrology. 3rd ed. Vol. 2. Baltimore: Williams & Wilkins, 1995:1148-65.
7. Comper WD, Glasgow EF. Charge selectivity in kidney ultrafiltration. Kidney Int 1995;47:1242-51.
8. Goode NP, Shires M, Davison AM. The glomerular basement membrane charge-selectivity barrier: an oversimplified concept? Nephrol Dial Transplant 1996;11:1714-6.
9. Bridges CR, Myers BD, Brenner, BM, Deen WM. Glomerular charge alterations in human minimal change nephropathy. Kidney Int 1982;22: 677-84.
10. Shemesh O, Ross JC, Deen WM, Grant GW, Myers BD. Nature of the glomerular capillary injury in human membranous glomerulopathy. J Clin Invest 1986;77:868-77.
11. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994;330:7-14.
12. Dantal J, Godfrin Y, Giral M, et al. Immunoapheresis with Ig-Therasorb in idiopathic nephrotic syndrome (INS) recurrence after renal transplantation (Tx). J Am Soc Nephrol 1996;7:1696. abstract.
13. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991;40:453-60.
14. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334:878-83.
15. Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ. Functional relationships in the nephrotic syndrome. Kidney Int 1984;26:324-30.
16. Van de Walle JG, Donckerwolcke RAMG, Greidanus TB, Joles JA, Koomans HA. Renal sodium handling in children with nephrotic relapse: relation to hypovolaemic symptoms. Nephrol Dial Transplant 1996;11: 2202-8.
17. Vande Walle JG, Donckerwolcke RAMG, van Isselt JW, Derkx FHM, Joles JA, Koomans HA. Volume regulation in children with early relapse of minimal change nephrosis with or without hypovolaemic symptoms. Lancet 1995;346:148-52.
18. Küster S, Mehls O, Seidel C, Ritz E. Blood pressure in minimal change and other types of nephrotic syndrome. Am J Nephrol 1990;10:Suppl 1: 76-80.
19. Plum J, Mirzaian Y, Grabensee B. Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome. Nephrol Dial Transplant 1996;11:1034-42.
20. Düsing R, Vetter H, Kramer HJ. The renin-angiotensin-aldosterone system in patients with nephrotic syndrome: effects of 1-sar-8-ala-angiotensin II. Nephron 1980;25:187-92.
21. Pool MO, Gans ROB, Donker AJM. Treatment of intractable chyluria by stripping of the kidneys. N Engl J Med 1990;323:552-3.
22. Koomans HA, Boer WH, Dorhout Mees EJ. Renal function during recovery from minimal lesions nephrotic syndrome. Nephron 1987;47:173-8.
23. Ichikawa I, Rennke HG, Hoyer JR, et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983;71:91-103.
24. Grausz H, Lieberman R, Earley LE. Effect of plasma albumin on sodium reabsorption in patients with nephrotic syndrome. Kidney Int 1972; 1:47-54.
25. Peterson C, Madsen B, Perlman A, Chan AYM, Myers BD. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans. Kidney Int 1988;34:825-31.
26. Perico N, Dalaini F, Lupini C, et al. Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney Int 1989;36:57-64.
27. Valentin J-P, Qiu CG, Muldowney WP, Ying W-Z, Gardner DG, Humphreys MH. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992;90:1302-12.
28. Wong KR, Xie M-H, Shi L-B, et al. Urinary cGMP as biological marker of the renal activity of atrial natriuretic factor. Am J Physiol 1988;255: F1220-F1224.
29. Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis 1987;10:157-71.
30. Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics 1993;91:1142-6.
31. Weiss RA, Schoenemann M, Greifer I. Treatment of severe nephrotic edema with albumin and furosemide. N Y State J Med 1984;84:384-6.
32. Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102:450-8.
33. Fliser D, Schröter M, Neubeck M, Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46:482-8.
34. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 1991;40: 418-24.
35. Olivero JJ, Frommer JP, Gonzalez JM. Medical nephrectomy: the last resort for intractable complications of the nephrotic syndrome. Am J Kidney Dis 1993;21:260-3.
36. Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;63:249-54.
37. Andrassy K, Ritz E, Bommer J. Hypercoagulability in the nephrotic syndrome. Klin Wochenschr 1980;58:1029-36.
38. Trew PA, Biava CG, Jacobs RP, Hopper J Jr. Renal vein thrombosis in membranous glomerulonephropathy: incidence and association. Medicine (Baltimore) 1978;57:69-82.
39. Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980;69:819-27.
40. Bernard DB. Extrarenal complications of the nephrotic syndrome. Kidney Int 1988;33:1184-202.
41. Wass V, Cameron JS. Cardiovascular disease and the nephrotic syndrome: the other side of the coin. Nephron 1981;27:58-61.
42. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42.
43. Robert A, Olmer M, Sampol J, Gugliotta JE, Casanova P Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 1987;31:830-5.
44. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994;45: 578-85.
45. Beaufils F, Schlegel N, Loirat C, Marotte R, Pillion G, Mathieu H. Urokinase treatment of pulmonary artery thrombosis complicating the pediatric nephrotic syndrome. Crit Care Med 1985;13:132-4.
46. Jones CL, Hebert D. Pulmonary thrombo-embolism in the nephrotic syndrome. Pediatr Nephrol 1991;5:56-8.
47. Markowitz GS, Brignol F, Burns ER, Koenigsberg M, Folkert VW. Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis 1995;25:801-6.
48. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994;46:287-96.
49. Vaziri ND. Nephrotic syndrome and coagulation and fibrinolytic abnormalities. Am J Nephrol 1983;3:1-6.
50. Fuchshuber A, Kühnemund O, Keuth B, Lütticken R, Michalk D, Querfeld U. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996;11:468-73.
51. Ogi M, Yokoyama H, Tomosugi N, et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994;24:427-36.
52. Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallès M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990;323:579-84.
53. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993;119:263-9.
54. Gansevoort RT, Heeg JE, Dikkeschei FD, de Zeeuw D, de Jong PE, Dullaart RPF. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994;9:244-50.
55. Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995;47:579-86.
56. Davies RW, Staprans I, Hutchinson FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990;86:600-5.
57. Chan MK, Persaud JW, Ramdial L, Varghese Z, Sweny P, Moorhead JF. Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal? Clin Chim Acta 1981;117:317-23.
58. Staprans I, Anderson CD, Lurz FW, Felts JM. Separation of a lipoprotein lipase cofactor from the alpha 1-acid glycoprotein fraction from urine of nephrotic patients. Biochim Biophys Acta 1980;617:514-23.
59. Kaysen GA, Myers BD, Couser WG, Rabkin R, Felts JM. Mechanisms and consequences of proteinuria. Lab Invest 1986;54:479-98.
60. Shafrir E, Brenner T. Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I. Studies in rat in vivo. Lipids 1979; 14:695-702.
61. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48: 1979-85.
62. Dullaart RPF, Gansevoort RT, Sluiter WJ, de Zeeuw D, de Jong PE. The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment. Metabolism 1996;45:723-30.
63. Wheeler DC. Lipids - what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant 1995;10:14-6.
64. D'Amico G, Gentile MG, Manna G, et al. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 1992;339:1131-4.
65. Hall AV, Parbtani A, Clark WF, et al. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J Am Soc Nephrol 1992;3:1321-9.
66. Spitalewitz S, Porush JG, Cattran D, Wright N. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 1993;22:143-50.
67. Thomas ME, Harris KPG, Ramaswamy C, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993;44:1124-9.
68. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-98.
69. Kaysen GA. Plasma composition in the nephrotic syndrome. Am J Nephrol 1993;13:347-59.
70. Grymonprez A, Proesmans W, Van Dyck M, Jans I, Goos G, Bouillon R. Vitamin D metabolites in childhood nephrotic syndrome. Pediatr Nephrol 1995;9:278-81.
71. Bergrem H. Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney Int 1983;23:876-81.
72. Miller PFW, Bowmer CJ, Wheeldon J, Brocklebank JT. Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child 1990;65: 196-200.
73. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
74. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-74.
75. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 1995;10:497-504.
76. Hemmelder MH, de Zeeuw D, Gansevoort RT, de Jong PE. Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney Int 1996;49:174-80.
77. Arisz L, Donker AJM, Brentjens JRH, van der Hem GK. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976;199:121-5.
78. Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993;44:579-84.
79. Weidmann P, Boehlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993;8:582-4.
80. Moriyama T, Kitamura H, Ochi S, et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995;6:1676-8.
81. Hutchison FN, Cui X, Webster SK. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Soc Nephrol 1995;6:1216-22.
82. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
83. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.
84. Donker AJM, Brentjens JRH, van der Hem GK, Arisz L. Treatment of the nephrotic syndrome with indomethacin. Nephron 1978;22:374-81.
85. Golbetz H, Black V, Shemesh O, Myers BD. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am J Physiol 1989;256:F44-F51.
86. Kaysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchison FN. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986;29:572-7.
87. Al-Bander H, Kaysen GA. Ineffectiveness of dietary protein augmentation in the management of the nephrotic syndrome. Pediatr Nephrol 1991;5:482-6.
88. Don BR, Kaysen GA, Hutchison FN, Schambelan M. The effect of angiotensin-converting enzyme inhibition and dietary protein restriction in the treatment of proteinuria. Am J Kidney Dis 1991;17:10-7.
89. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial Mediterranean fever: a double-blind trial. N Engl J Med 1974;291:934-7.
90. Lin C-Y. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995;47:225-30.
91. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
92. Dimitrov Y, Heibel F, Marcellin L, Chantrel F, Moulin B, Hannedouche T. Acute renal failure and nephrotic syndrome with alpha interferon therapy. Nephrol Dial Transplant 1997;12:200-3.
93. Covic A, Mititiuc I, Caruntu L, Goldsmith DJA. Reversible nephrotic syndrome due to mesangiocapillary glomerulonephritis secondary to hepatic hydatid disease. Nephrol Dial Transplant 1996;11:2074-6.
94. Kassirer JP. Is renal biopsy necessary for optimal management of the idiopathic nephrotic syndrome? Kidney Int 1983;24:561-75.
95. Primack WA, Schulman SL, Kaplan BS. An analysis of the approach to management of childhood nephrotic syndrome by pediatric nephrologists. Am J Kidney Dis 1994;23:524-7.
96. Adu D. The nephrotic syndrome: does renal biopsy affect management? Nephrol Dial Transplant 1996;11:12-4.
97. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int 1986;29:1215-23.
98. Hergesell O, Felten H, Andrassy K, Kühn K, Ritz E. Safety of ultrasound-guided percutaneous renal biopsy - retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant 1998;13:975-7.
99. Black DAK, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. BMJ 1970;3:421-6.
100. Ponticelli C. Focal segmental glomerular sclerosis: to treat or not to treat? 1. It is worthwhile to give the adult patient with nephrotic syndrome the benefit of an adequate therapeutic trial? Nephrol Dial Transplant 1995; 10:2351-4.
101. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996;7:56-63.
102. Meyrier A, Noel L-H, Auriche P, Callard P, Collaborative Group of the Société de Néphrologie. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994;45: 1446-56.
103. Gregory MJ, Smoyer WE, Sedman A, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 1996;7:543-9.
104. Ingulli E, Tejani A. Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol 1992;3:254-9.
105. Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997;8:824-32.
106. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-4.
107. Piccoli A, Pillon L, Passerini P, Ponticelli C. Therapy for idiopathic membranous nephropathy: tailoring the choice by decision analysis. Kidney Int 1994;45:1193-202.
108. Ambalavanan S, Fauvel J-P, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996;7:290-8.